Abiopharma

🔍 Bergmann Anthony (Executive)

Company: CAPRICOR THERAPEUTICS, INC. (CAPR)

Report Date: 2026-03-31

Detailed Transactions and Holdings:

• Acquired 25,000 shares of Common Stock at $3.18 per share (Direct)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 33,223.00 | transaction_form_type: 4
• Sold 25,000 shares of Common Stock at $30.1261 per share (Direct)
  Date: 2026-03-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 8,223.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 25,000 shares of Stock Option (Right to Buy) at $3.18 per share (Derivative)
  Date: 2026-03-31 | Code: M | Expires: 2032-01-03 | equity_swap_involved: 0 | shares_owned_after: 141,980.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• F2: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.32, inclusive.
• F3: Shares vested 1/48th on the first day of each month commencing February 1, 2022.